Overview

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC